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Abstract
Background: Erysipelothrix rhusiopathiae is an established animal pathogen, which may cause infections in humans.
It is a gram-positive rod and found in the tonsils or the digestive tracts of animals. The bacterium is occupationally
related, as usually only people with frequent animal contacts are infected. We report a case of a patient who was
admitted with an infectious tenosynovitis with bloodstream infection due to E. rhusiopathiae, and to our
knowledge, this is the first report of a tenosynovitis with systemic manifestation associated with this bacterium.
Case presentation: A 52-year old Norwegian man, who worked with transportation of swine cadavers, was
admitted to the local hospital with sepsis and unknown focus of infection. A few days earlier he had an injury to
the skin of one of his fingers that later proved to be infected with E. rhusiopathiae. There were no other causes for
his symptoms than the infectious tenosynovitis with systemic manifestation. The infection resolved on treatment
with antibiotics and surgery. A transoesophageal echocardiogram was performed to exclude endocarditis, which
may be associated with this pathogen.
Conclusions: This case report highlights the importance of clinicians being aware of this bacterium, and we
describe risk factors for infection, differences in the clinical manifestations of the disease, challenges with
diagnosing the bacterium and adverse effects of immunosuppressive drugs. Recommended treatment is
appropriate antibiotic therapy and adequate debridement and surgical drainage of the tendon sheath.
Keywords: Erysipelothrix rhusiopathiae, Infectious tenosynovitis, Sepsis, Bloodstream infection, Endocarditis, Surgical
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Background
Erysipelothrix rhusiopathiae is described as a non-motile,
non-sporulating, non-acid-fast, slender gram-positive rod
with capsule, which is easily decolourised. The rod is re-
covered from the tonsils or the digestive tracts of different
animals [1]. Swine is believed to be the major reservoir of
E. rhusiopathiae, but rodents and birds are also frequently
infected. The bacterium also grow and persist in mucoid
exterior slime in fish [2]. Humans can be infected from
contact with these animals, their secretions, wastes or
products, or contaminated organic matter [1].
E. rhusiopathiae causes mainly three types of infec-
tions in humans. Firstly, a mild cutaneous infection
(erysipeloid), described as a local cellulitis, usually on
the hands or fingers. The disease is self-limiting within
3–4 weeks without therapy, but if not treated with antibi-
otics there is a risk of relapse. Secondly, it may cause a dif-
fuse cutaneous infection where the patient experiences
that the local lesions spread to other locations of the body
and bullous lesions may coexist with systemic symptoms
such as fever, malaise, headache, joint- and muscle pain.
Some patients also experience polyarthritis. Lastly, E. rhu-
siopathiae may cause septicaemia and endocarditis [1, 2].
* Correspondence: Arne.Mehl@helse-nordtrondelag.no
2Department of Medicine, Levanger Hospital, Nord-Trøndelag Hospital Trust,
Levanger, Norway
6Mid-Norway Sepsis Research Group, Norwegian University of Science and
Technology, Trondheim, Norway
Full list of author information is available at the end of the article
© The Author(s). 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Hofseth et al. BMC Infectious Diseases  (2017) 17:12 
DOI 10.1186/s12879-016-2102-1
Penicillin G is the drug of choice to treat infections caused
by this bacterium [2].
Infectious tenosynovitis refers to the infection of a ten-
don and its synovial sheath. In the setting of tenosyno-
vitis, the space between the inner visceral layer adherent
to the tendon and an outer parietal layer may be filled
with inflammatory or purulent fluid. Bacteria can enter
the tendon sheath by direct inoculation via trauma or
spread from infected adjacent soft tissues. It may also
spread hematogenously. The most common pathogens
are skin flora (i.e., gram-positive cocci such as Staphylo-
coccus aureus and streptococci) [3, 4]. Recommended
treatment for this type of infection is appropriate
antibiotic therapy, adequate debridement and surgical
drainage, a period of immobilisation and elevation of
the extremity, and early mobilisation. Appropriate tet-
anus prophylaxis is necessary [4].
Hereby, we describe the successful management of a
patient who was admitted with an infectious tenosyno-
vitis with bloodstream infection due to E. rhusiopathiae.
Only once in published literature there has been de-
scribed tenosynovitis caused by this bacterium, as a local
infection [5]. To our knowledge, this case report shed
new light on the pathogenesis of this disease being the
first known report of a tenosynovitis with systemic
manifestation associated with this bacterium.
Case presentation
Admission
A 52-year-old man was admitted to the local hospital
because of acute fever and poor general condition. By
admittance he was septic with unknown focus of infec-
tion. He worked in the transportation business and
mainly by transportation of cadavers, most often swine
cadavers. He rarely used protective gloves. He had
known ankylosing spondylitis since years and was treated
with adalimumab injections every 14 days and ibuprofen.
He had earlier experienced a reaction to penicillin with
symptoms of urticaria. Five days before admission he got a
cut on the volar side of the proximal inter phalangeal joint
of the fourth finger on the left hand, but he could not re-
member how he got it. Two days later he had increasing
pain in his finger and it swelled, but no pus was seen from
the wound. The last 24 h before admission, he experi-
enced fever with chills, increasing pain in the finger,
nausea, diarrhoea and fatigue.
On physical examination at admission, his body
temperature (after taking antipyretics) was 38.4°C, pulse
rate was 93 beats per minute, respiratory rate was 20 per
minute, and blood pressure was 147/92 mmHg. By aus-
cultation the lung sounds were normal and there was no
cardiac murmur. The abdomen was soft and free from
pain by palpation. Examination of the fourth finger on
the left hand showed a small, dry wound from the cut,
some tenderness along the course of the flexor sheath,
slightly flexed finger at rest, erythema and enlargement
compared to the other digits.
Laboratory and imaging examinations showed white
blood cells (WBC) 18.3 × 109/L, neutrophil granulocytes
16.4 × 109/L, haemoglobin 13.7 g/L, platelets 300 × 109/L,
C-reactive protein (CRP) 15 mg/L, lactate dehydrogenase
287 U/L. Blood cultures (three bottles from one
venipuncture) were sampled. The chest X-ray was normal
and he had a normal urine dipstick test. In conclusion the
patient fulfilled 4/4 systemic inflammatory response syn-
drome (SIRS) criteria and the most plausible explanation
was sepsis due to a bacterial tenosynovitis in the fourth
finger of the left hand. Based on this the patient was rap-
idly brought to the operating room.
Therapeutic intervention
In local anaesthetic ulnar and median nerve block an in-
cision was made to reach the common synovial sheath
2–3 cm proximally to the basis of the fourth finger. Im-
mediately accumulated fluid emptied the synovial sheath
and a bacterial sample was collected. In accordance with
Norwegian sepsis guidelines in patients allergic to peni-
cillin, the patient was then given clindamycin and genta-
micin intravenously. Furthermore, two incisions on the
volar side of the proximal and distal interphalangeal
joints through the synovial sheath were made and a
drain tube was inserted into the sheath from the palm of
the hand to the distal interphalangeal joint. The drain
tube was connected to Ringer’s acetate that flushed the
tendon sheath until the next day.
Recovery and discharge
The day after the patient was feeling much better. He
had no fever and did not appear septic. Laboratory ex-
aminations showed: WBC 19.7 × 109/L; CRP 73 mg/L.
Three out of three blood cultures bottles were positive
with gram-positive rods, and gram-positive cocci in clus-
ters, probably staphylococci, were found in the sample
from the synovial sheath. The patient was referred for
transthoracic echocardiography to exclude endocarditis
and the echocardiogram showed morphologically normal
valves and chambers with no signs of vegetations. After
4 days of intravenous treatment with clindamycin
600 mg × 3/day and gentamicin 320 mg × 1/day, the pa-
tient was discharged in well-being. CRP had fallen to
11 mg/L and WBC to 9.3 × 109/L. He continued with
clindamycin orally 300 mg × 3/day for 1 week. He was
recommended to avoid the upcoming injection of
adalimumab at discharge.
Five days after discharge, a transoesophageal echocar-
diogram was performed with no signs of valvular or
endocardial manifestation of the disease. He was recom-
mended to see his general practitioner for a clinical
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follow-up and removal of the stitches 1 week after dis-
charge. At an outpatient control after three months and
when we contacted him ten months after discharge, the
patient reported no relapse of the infection and no per-
sistent sequela.
Verifying the rod
A blood culture set including two aerobic bottles and one
anaerobic bottle was sampled immediately at admission.
Within the first 24 h of incubation in 35°C, all three bot-
tles turned positive. The gram stain showed gram-positive
rods (Fig. 1). Due to characteristic V-formation when
visualised in the microscope, they could easily be mistaken
for Corynebacterium sp. Because of this we did an initial
susceptibility test, directly from positive bottles, based on
antibiotics used on Corynebacterium sp. according to
Nordic Committee on Antimicrobial Susceptibility Testing
(NordicAST) guidelines with disc diffusion method [6].
The isolate was susceptible to penicillin, clindamycin, cip-
rofloxacin, linezolid and doxycycline and was resistant to
gentamicin and rifampicin.
After six to eight hours there were signs of growth on
agar plates, but not enough for further examination.
After 24 h of incubation, there was growth on both aer-
obic and anaerobic agar plates. Identification of the iso-
late was achieved by automatically testing with BD
Phoenix 100. It was identified as E. rhusiopathiae with
99% confidence value. Confirmation of the result by the
Maldi-tof system was done at the regional university ref-
erence laboratory. Due to the patient’s history, the isola-
tion of this bacterium was expected.
A second susceptibility test was done from cultured
bottles to determine the minimum inhibitory concentra-
tion value of the antibiotics (MIC), using NordicAST
guidelines on non-species related breakpoints. MIC-
testing showed the isolate was susceptible to penicillins,
cephalosporins, ciprofloxacin, clindamycin, erythromycin
and imipenem. The isolate was resistant to gentamicin,
trimethoprim-sulfa and vancomycin.
During surgery two samples from the synovial sheath
were collected and these were also cultured. One sample
was sterile, Staphylococcus aureus alone was found in
the other. The isolate was, among others, susceptible to
clindamycin and gentamicin. This bacterium was not de-
tected in the blood cultures.
Discussion
We have described a rare invasive E. rhusiopathiae in-
fection and several lessons can be learned from this case.
Swine are the most important animal reservoir of E.
rhusiopathiae, which is shed by infected animals in fae-
ces, urine, saliva and nasal secretions [1]. Our patient
worked with transportation of swine cadavers, and thus,
he had an occupational risk for such infections. We
know that 20–40% of healthy swine harbour this pathogen
in their lymphoid tissue of the alimentary tract, particu-
larly in the tonsils [1]. Infections caused by E. rhusio-
pathiae are strongly related to the occupation of the
patient and almost 90% of patients with endocarditis due
to this pathogen have an occupational risk of infection [7].
Most often infection with E. rhusiopathiae is initiated
either by an injury to the skin with infective material or
by contamination of a previous injury. There have also
Fig. 1 Gram stain smear of E. rhusiopathiae from a blood culture bottle. The arrows point toward Gram positive rods with V-formation, a characteristic
way the bacteria group together
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been a few documented cases of penetration through the
skin by this bacterium [1]. Our patient rarely used pro-
tective gloves, and he had a cut in one of his fingers a
few days before admission. We believe that contamin-
ation of this injury was the cause of the infection. Due
to changes in technology in the animal industry, it has
been suggested that the frequency of human infection by
this pathogen is decreasing [2]. However, in some environ-
ments, exposure to E. rhusiopathiae is maintained, and
the threat of infections is present. Preventive initiatives in-
clude good hygiene with frequent hand washing, use of
protective gloves and cleansing of wounds. Removal or
regular disinfection of contaminated sources is important
to limit the spread of the bacterium as well [1].
Our patient was diagnosed with ankylosing spondylitis
since years and was treated with adalimumab, a tumour
necrosis factor-alpha (TNF-α) inhibitor. TNF-α is an
important component of the immune response to a variety
of infections. Thus, the use of such medication has been
associated with an increased risk of serious infections [8],
including infective tenosynovitis [4]. As the American
College of Rheumatology recommends not to administer
TNF-α inhibitors to patients with active bacterial infections
[9], our patient was instructed not to take the subsequent
dose of adalimumab. Depression of the immune system
predisposes to the development of systemic infections with
among other E. rhusiopathiae, and thus, the risk of sys-
temic infections, as endocarditis, is also increased [7].
Reports show that systemic infection with E. rhusio-
pathiae occur in less than 1% of cases, but in 90% of
these there is an association with endocarditis [1, 7]. The
first case of endocarditis with E. rhusiopathiae was re-
ported in 1912, but since then no more than 80 cases of
endocarditis caused by E. rhusiopathiae have been re-
ported [7]. This cause of endocarditis is therefore ex-
tremely rare [7, 10]. However, endocarditis caused by E.
rhusiopathiae has a high case fatality rate of approxi-
mately 40% [10, 11]. Due to these reasons the echocar-
diographic examinations included a transoesophageal
approach as this is more sensitive to reveal endocardial
manifestations, and an echocardiographic examination
was repeated after 6 days. E. rhusiopathiae is reported to
be susceptible to penicillin, cephalosporin, imipenem,
clindamycin, and fluoroquinolones, but it is often non-
susceptible to macrolides and chloramphenicol, and
resistant to sulphonamides, vancomycin and aminoglyco-
sides [10]. The first-line empiric therapy for a presumed
endocarditis in patients allergic to penicillin include
vancomycin and aminoglycosides, which have no effect
against E. rhusiopathiae [2, 7]. It is therefore important to
reveal the correct diagnosis to avoid delayed administra-
tion of appropriate drugs. The recommended treatment in
patients with endocarditis due to this bacterium is penicil-
lin G given intravenously for a total duration of 4–6 weeks
[2]. Alternatively, patients with an E. rhusiopathiae infec-
tion and coexisting allergy to penicillin can be treated with
cephalosporin or fluoroquinolone [2, 12].
Due to sepsis and presumed allergy to penicillin, the pa-
tient was treated with an aminoglycoside, to which the bac-
terium was resistant, and clindamycin. Clindamycin may
be bactericide in high concentrations [12]. Our patient
responded well to the treatment and did not fill the SIRS-
criteria the day after surgery. Thus, we decided to continue
with clindamycin orally after discharge for one week. The
patient received antibiotic therapy for 12 days in total. The
optimal duration of antibiotic therapy for E. rhusiopathiae
bloodstream infection is unknown and has not been evalu-
ated in clinical trials. Thus, the duration of antibiotic ther-
apy in patients with bacteremia, but without endocarditis,
must be based on the clinical response to the treatment
provided and the patient’s underlying health condition.
The diagnosis of E. rhusiopathiae can be challenging. In
this case the blood cultures revealed E. rhusiopathiae, but
in the sample from the tendon sheath only S. aureus was
found. This may be caused by the slow growth of the bac-
terium and the small sizes of its colonies. E. rhusiopathiae
can be overgrown with secondary pathogens such as S.
aureus and S. pyogenes. We believe that this is what hap-
pened with the cultured samples from the tendon sheath.
The diagnosis of this pathogen can therefore be challenging
if the bacteriologists are not aware of the clinical suspicion
of potential contamination from animal contact [1]. Thus,
infections with E. rhusiopathiae may be under-diagnosed.
According to our recommendations, two blood culture
sets from two separate venipunctures should be drawn.
In this case, probably because of time constraints, only
one blood culture set including two aerobic bottles and
one anaerobic bottle was sampled. We have still judged
this case to be a real bloodstream infection, as it is un-
likely that E. rhusiopathiae should occur as a skin con-
taminant at the venipuncture site.
Conclusion
This case report shed new light on the pathogenesis of
infections with E. rhusiopathiae being the first known
report of a tenosynovitis with bloodstream infection as-
sociated with this pathogen. Recommended treatment
for this type of infection is appropriate antibiotic therapy
and adequate debridement and surgical drainage. Due to
the slow growth of the bacterium, the small sizes of its
colonies, and the risk that it can be overgrown with sec-
ondary pathogens, the diagnosis of this pathogen is chal-
lenging if bacteriologists are not aware of the clinical
suspicion of potential contamination from animal contact.
This shows the importance of both comprehensive med-
ical history and accurate and detailed information accom-
panying samples to the microbiology laboratory. Even
though E. rhusiopathiae is a rare cause of endocarditis or
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other systemic infections, endocarditis is associated with
high case fatality rate. E. rhusiopathiae is reported to be
resistant to vancomycin and aminoglycosides, which rep-
resent the first-line empiric therapy for a presumed endo-
carditis in patients allergic to penicillin. This highlights
the importance of revealing the correct diagnosis to avoid
delayed administration of appropriate drugs.
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